Home › Disturbo depressivo maggiore › Ohio
Studi clinici su Disturbo depressivo maggiore nello stato di Ohio
29 studi su Disturbo depressivo maggiore cercano partecipanti presso sedi nello stato di Ohio.
Città nello stato di Ohio
Testo ufficiale dello studio (inglese)
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
- Patient Priority Clinical Sites LLC, Cincinnati
In reclutamentoFase 3
Età da 18 a 74 · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT07573176Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- Patient Priority Clinical Sites LLC, Cincinnati
- The Ohio State University, Columbus
In reclutamentoFase 3
Età da 18 a 74 · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06559306Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- Quest Therapeutics of Avon Lake, Avon Lake
- University of Cincinnati Medical Center, Cincinnati
- The Ohio State University, Columbus
In reclutamentoFase 3
Età da 18 a 65 · Tutti i sessi · Aggiornato il 25 set 2026 · NCT05850689A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
- University of Cincinnati, Cincinnati
In reclutamentoFase 3
Età da 12 a 17 · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07227454Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
- Vanda Investigational Site, Cincinnati
In reclutamentoFase 3
Età da 18 a 65 · Tutti i sessi · Aggiornato il 24 set 2026 · NCT06830044A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- Neurocrine Clinical Site, Independence
In reclutamentoFase 4
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 set 2026 · NCT07105111A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
- Seaport Investigator Site, Independence
- Seaport Investigator Site, North Canton
In reclutamentoFase 2
Età da 18 a 65 · Tutti i sessi · Aggiornato il 14 set 2026 · NCT07065240ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
- Neuro-Behavioral Clinical Research, North Canton
In reclutamentoFase 2
Età da 18 a 65 · Tutti i sessi · Aggiornato il 14 set 2026 · NCT07284667A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- Insight Clinical Trials, Independence
In reclutamentoFase 3
Età da 18 a 74 · Tutti i sessi · Aggiornato il 8 set 2026 · NCT07076407A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
- Draig Clinical Site, Columbus
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 2 set 2026 · NCT07610473Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
- The Cleveland Clinic Foundation, Cleveland
- The Ohio State University, Columbus
In reclutamento
Età da 22 a 70 · Tutti i sessi · Aggiornato il 28 ago 2026 · NCT06423430Positive Processes and Transition to Health (PATH)
- Case Western Reserve University, Cleveland
In reclutamento
Età da 18 a 65 · Tutti i sessi · Aggiornato il 19 ago 2026 · NCT06093906NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Mason
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 11 ago 2026 · NCT06911112A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
- Cleveland Clinic, Cleveland
In reclutamentoFase 3
Età da 18 a 74 · Tutti i sessi · Aggiornato il 10 ago 2026 · NCT07592689Modulating Spinal Interoceptive Pathways to Evaluate Their Role and Therapeutic Potential in MDD Symptomatic Domains
- Lindner Center of Hope, Mason
In reclutamentoFase 1/2
Età da 18 a 60 · Tutti i sessi · Aggiornato il 3 ago 2026 · NCT06795451A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
- Neuro-Behavioral Clinical Research, North Canton
In reclutamentoFase 3
Età da 18 a 74 · Tutti i sessi · Aggiornato il 3 ago 2026 · NCT06775379Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- Insight Clinical Trials LLC, Independence
In reclutamentoFase 2
Età da 18 a 64 · Tutti i sessi · Aggiornato il 3 ago 2026 · NCT06547489A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- Insight Clinical Trials LLC, Independence
In reclutamentoFase 2
Età da 18 a 64 · Tutti i sessi · Aggiornato il 27 lug 2026 · NCT07115329Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Avon Lake
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 lug 2026 · NCT06966401Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
- Clinical Research Site, Cincinnati
- Clinical Research Site, Cincinnati
In reclutamentoFase 3
Età da 18 a 65 · Tutti i sessi · Aggiornato il 24 lug 2026 · NCT07484217A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety
- The Ohio State University Department of Psychiatry, Columbus
In reclutamentoFase 2
Età da 21 a 65 · Tutti i sessi · Aggiornato il 23 lug 2026 · NCT06820723A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
- Quest Therapeutics of Avon /ID# 277550, Avon Lake
- OSU Psychiatry Department /ID# 277529, Columbus
In reclutamentoFase 2
Età da 18 a 65 · Tutti i sessi · Aggiornato il 15 giu 2026 · NCT07276997A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
- The Ohio State University, Columbus
- Neuro Behavioral Clinical Research, Inc., North Canton
In reclutamentoFase 2
Età da 18 a 65 · Tutti i sessi · Aggiornato il 11 mag 2026 · NCT06524830Improving Outcomes in Adolescent Inpatient Depression With Deep Transcranial Magnetic Stimulation
- Cincinnati Childrens Hospital Medical Center, Cincinnati
In reclutamento
Età da 14 a 18 · Tutti i sessi · Aggiornato il 11 feb 2026 · NCT07217444Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
- Autobahn Site #109, Beachwood
In reclutamentoFase 2
Età da 18 a 65 · Tutti i sessi · Aggiornato il 20 gen 2026 · NCT06633016Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Avon Lake
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 ott 2025 · NCT06786624Mechanisms of Rumination Change in Adolescent Depression
- Nationwide Children's Hospital, Columbus
- The Ohio State University, Columbus
In reclutamento
Età da 14 a 17 · Tutti i sessi · Aggiornato il 11 ago 2025 · NCT03859297Study of ALTO-300 in MDD
- Site 202, Cincinnati
In reclutamentoFase 2
Età da 18 a 70 · Tutti i sessi · Aggiornato il 24 lug 2025 · NCT05922878A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
- Clinical Research Site, Cincinnati
In reclutamentoFase 4
Età da 18 a 65 · Tutti i sessi · Aggiornato il 23 gen 2025 · NCT06223880Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.